What Axoltis Pharma does

Axoltis Pharma is a clinical-stage French biotechnology company developing first-in-class therapeutics for degenerative and traumatic neurological disorders with high unmet medical needs. The company's lead asset, NX210c, is a 12 amino-acid synthetic peptide (a Thrombospondin Repeat analog) inspired by SCO-spondin, a multifunctional glycoprotein essential in neurogenesis. NX210c is designed around a single mechanistic thesis: that blood-brain barrier (BBB) dysfunction is a central driver of neurodegeneration across multiple diseases. The molecule combines three properties — BBB restoration, neuroprotection against glutamate excitotoxicity and oxidative stress, and enhancement of synaptic neurotransmission — that together aim to halt disease progression rather than address a single downstream symptom.

Axoltis is currently executing the SEALS Phase 2 clinical trial, evaluating NX210c in 82 ALS patients across 16 clinical centers in France, with topline efficacy and tolerability results expected in Q2 2026. The clinical program is anchored by Orphan Drug Designation granted by both the FDA and EMA for ALS, and supported by 7 fully owned patent families including composition of matter granted in the EU, USA, and Japan. The pipeline extends beyond ALS to Multiple Sclerosis (with active in silico QSP modeling via InSilicoTrials Technologies), Alzheimer's Disease, Parkinson's Disease, and Spinal Cord Injury, all sharing BBB dysfunction as the underlying pathology. The company has built a scientific and operational network spanning Trinity College Dublin, University of Eastern Finland, CNRS, Texas A&M University, the CRO Neuro-Sys, and patient associations (ARSLA, Fondation SLA Suisse, Act 4 ALS).

The company has no commercial revenue. Its revenue model is future one-time licensing or commercialization of NX210c upon regulatory approval; until then, it is funded by dilutive equity (€18 million Series A closed December 2025, led by Cenitz and FIDAT Ventures) and public/private support (Bpifrance, Lyonbiopole, regional Auvergne-Rhône-Alpes programs). The team is small (1-10 employees), operating from Clermont-Ferrand (headquarters) and a Lyon secondary office in the Bioparc Laennec. Customer-facing activity is limited to clinical trial conduct, with partnership discussions with global pharmaceutical companies identified as an explicit use of Series A proceeds.

Name

Axoltis Pharma

Legal name

Axoltis Pharma

Website

https://axoltis.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Axoltis Pharma is a clinical-stage French biotech developing NX210c, a synthetic peptide that restores blood-brain barrier integrity, for ALS and other neurodegenerative diseases, currently in Phase 2 trials with results expected Q2 2026.

Ownership category

akta.pro rank

Product category

Neurological Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Neurodegenerative drug development
• Peptide therapeutics
• ALS treatment
• Blood-brain barrier repair
• Central nervous system disorders

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. Pharmaceutical Drug Development: Pre-revenue biotech company developing NX210c drug candidate through clinical trials. Revenue will be generated through drug commercialization upon regulatory approval.

Distribution channels1 record

Marketing channels2 records

Core offering

Axoltis Pharma is a clinical-stage French biotech company developing NX210c, a 12-amino-acid synthetic peptide drug candidate inspired by SCO-spondin, designed to restore blood-brain barrier integrity, provide neuroprotection, and enhance neurotransmission for the treatment of neurodegenerative and traumatic neurological disorders. The lead indication is Amyotrophic Lateral Sclerosis (ALS), with Phase 2 SEALS clinical trial topline results expected Q2 2026.

Product overview

Axoltis Pharma operates as a clinical-stage biotech company with a single lead drug candidate, NX210c, currently in Phase 2 development. The company is not organized as a platform-plus-modules architecture; rather, it is focused exclusively on advancing NX210c through clinical development for neurodegenerative diseases. The product pipeline includes Multiple Sclerosis and other CNS disorders as potential future indications, with the core product being an innovative peptide therapeutic targeting blood-brain barrier integrity.

Differentiator

Problem solved

Functional benefit

Products and services

• NX210c

Quantifiable outcome

• Phase 2 SEALS trial evaluating efficacy and tolerability in 82 ALS patients with results expected Q2 2026
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered supporting.

• LyonbiopolesupportingStrategic or Co-development PartnerCluster supporting biotechnology and medtech companies in the Lyon area.
• Neuro-SyssupportingTechnology or IntegrationCRO specializing in neurodegenerative disorders; Dr. Noelle Callizot is CSO and co-founder.
• InSilicoTrials TechnologiessupportingTechnology or IntegrationTechnology partner for in silico QSP simulation and modeling for Multiple Sclerosis indication.
• Trinity College DublinsupportingTechnology or IntegrationScientific partner with Prof. Matthew Campbell providing expertise in blood-brain barrier research. Prof. Campbell serves on the Scientific Advisory Board.
• University of Eastern FinlandsupportingTechnology or IntegrationAcademic research partner in neuroscience and blood-brain barrier studies.
• CNRSsupportingTechnology or IntegrationFrench National Center for Scientific Research - academic partner in research collaborations.
• Texas A&M UniversitysupportingTechnology or IntegrationAcademic research partner in neuroscience and biotechnology.
• ARSLAsupportingOthersFrench patient association supporting ALS patients and research.
• Act 4 ALSsupportingOthersPatient advocacy organization for ALS research and patient support.
• Fondation SLA SuissesupportingOthersSwiss foundation supporting ALS research and patient advocacy.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Alector: Alector is a clinical-stage immuno-neurology biotech developing monoclonal antibodies for neurodegenerative diseases including frontotemporal dementia and Alzheimer's. It is an emerging peer in CNS drug development with a similar late-clinical-stage risk profile and large-pharma partnership model (with AbbVie).
• Denali Therapeutics: Denali is a clinical-stage biotech developing BBB-penetrant therapeutics (including enzyme and protein degraders) for ALS, Parkinson's, and other neurodegenerative diseases. It is an emerging peer whose BBB-trafficking platform is directly adjacent to Axoltis's BBB-restoration thesis.
• QurAlis: QurAlis is an emerging US-based precision medicine biotech developing genetically targeted therapies for ALS, including splice-modulating and TDP-43 programs. It is an emerging ALS peer with a different (genetic) approach but overlapping patient population and ODD strategy.
• Helixmith: Helixmith is a clinical-stage biotech developing Engensis (VM202), a plasmid DNA therapy, for ALS and other neurodegenerative indications. It is an emerging peer in orphan ALS drug development with a comparable small-cap, single-asset profile.

Direct peers

• Cytokinetics: Cytokinetics is a clinical-stage biopharmaceutical company developing novel muscle activators for ALS (e.g., reldesemtiv) and other diseases of impaired muscle function. It is a direct peer in the orphan ALS therapeutics space, with comparable single-indication focus, similar regulatory pathway (ODD), and overlapping clinical centers in the US/EU.
• Clene Nanomedicine: Clene is a clinical-stage nanomedicine company developing CNM-Au8, a gold nanocatalyst, for ALS and other neurodegenerative diseases. It is a direct peer in orphan ALS drug development with a similar capital structure and a single lead asset advancing through Phase 2/3.
• BrainStorm Cell Therapeutics: BrainStorm is a clinical-stage biotech developing NurOwn, an autologous cell therapy for ALS. It is a direct peer competing in the same orphan ALS market with a different modality (cell therapy vs. peptide), facing similar regulatory and capital intensity challenges.
• AB Science: AB Science is a French clinical-stage pharma company developing masitinib for ALS and other neurodegenerative/inflammatory conditions. It is a directly comparable peer — small French sponsor, orphan CNS indication, late-stage pivotal trials, similar capital-constrained profile.

Broad incumbents

• Biogen: Biogen is a large neuroscience-focused biopharma with an approved ALS therapy (Qalsody/tofersen) and broad CNS pipeline. It is a broad incumbent in the same disease space and a likely potential acquirer or partner for late-stage ALS assets like NX210c.
• Ionis Pharmaceuticals: Ionis is a leading antisense oligonucleotide platform company with multiple ALS programs (in partnership with Biogen). It is a broad incumbent competing in CNS, including for ALS patients, and a potential partner for peptide-based BBB targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/axoltis-pharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axoltis Pharma